Principal Financial Group
CTXR icon

Principal Financial Group’s Citius Pharmaceuticals CTXR Stock Holding History

Principal Financial Group’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-626
Closed -$14K – 2391
2024
Q1 		$14K Sell
626
-64
-9% -$1.17K ﹤0.01% 2417
2023
Q4 		$13K Hold
690
– – ﹤0.01% 2404
2023
Q3 		$11.8K Buy
690
+146
+27% +$3.47K ﹤0.01% 2427
2023
Q2 		$16.3K Buy
+544
New +$17.9K ﹤0.01% 2409
2022
Q2 		– Sell
-662
Closed -$30K – 2535
2022
Q1 		$30K Sell
662
-37
-5% -$1.46K ﹤0.01% 2507
2021
Q4 		$27K Buy
+699
New +$31.7K ﹤0.01% 2503
2021
Q3 		– Sell
-524
Closed -$46K – 2588
2021
Q2 		$46K Buy
+524
New +$31.5K ﹤0.01% 2578

Other funds holding CTXR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Principal Financial Group's CTXR Position: Q2 2024 in Review

Principal Financial Group sold out of Citius Pharmaceuticals (CTXR) in Q2 2024, closing a stake of 626 shares — an estimated $14K sold.

Principal Financial Group first reported a position in CTXR in Q2 2021 and held it in 7 quarters. The position peaked at $46K in Q2 2021. 72 funds tracked by Wall St. Rank hold CTXR as of Q2 2024.

  • Principal Financial Group reported no remaining Citius Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Principal Financial Group sold 626 Citius Pharmaceuticals shares in Q2 2024, an estimated $14K.
  • Principal Financial Group first reported a position in Citius Pharmaceuticals in Q2 2021 and held it in 7 quarters.
  • Principal Financial Group's Citius Pharmaceuticals position peaked at $46K in Q2 2021.
  • 72 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2024.

Based on Principal Financial Group's 13F filing for Q2 2024, filed 29 Jul 2024.